OLIVIA VISE: Open Payments
NPI 1841663051 · BIRMINGHAM, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,585 in 204 payments from 23 companies in 2025. Trend: 2023 $3,067 · 2024 $3,412 · 2025 $4,585
Food & beverage: $4,472Education: $113
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 42 | $863 |
| GENZYME CORPORATION | 16 | $465 |
| Regeneron Healthcare Solutions, Inc. | 18 | $421 |
| GlaxoSmithKline, LLC. | 25 | $400 |
| Insmed, Inc. | 15 | $338 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $321 |
| Amgen Inc. | 15 | $280 |
| Grifols USA, LLC | 9 | $258 |
| JAZZ PHARMACEUTICALS INC. | 9 | $203 |
| Viatris Specialty LLC | 9 | $172 |
Products named: DUPIXENT, TEZSPIRE, Arikayce, GLASSIA, AIRSUPRA, FASENRA, NUCALA, Prolastin-C Liquid.
Industry payments across AL — which companies pay providers there.
